The leukapheresis market is experiencing significant growth, driven by the increasing adoption of CAR-T cell therapies and advanced immunotherapies that require the efficient collection of white blood cells from patients. As the prevalence of hematological malignancies, such as leukemia and lymphoma, continues to rise, the demand for leukapheresis procedures is also increasing. These procedures serve as both a crucial therapeutic intervention and an essential method for cell collection in transplantation.